Literature DB >> 7683250

Biological consequences of overexpression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells.

M Noguchi1, M Murakami, W Bennett, R Lupu, F Hui, C C Harris, B I Gerwin.   

Abstract

In order to examine the effects of the overexpression of c-erbB-2 (HER-2, neu) on human bronchial epithelial cells, a human c-erbB-2 expression vector was introduced into the simian virus 40 large T-antigen-immortalized human bronchial epithelial cell line BEAS-2B. Isolation of multiple clonal cell lines after selection revealed a wide range of expression of the gene product gp185erbB-2. While three of six clones tested expressed gp185erbB-2 at levels detectable by immunocytochemistry, only one, B2BE6, induced adenocarcinoma-like tumors in athymic nude mice. Both a nontumorigenic clone, B2BE2, and a tumorigenic clone, B2BE6, expressed comparable amounts of gp185erbB-2, which became phosphorylated on tyrosine in response to treatment with the c-erbB-2 ligands gp30 and p75. These data suggest that overexpression of c-erbB-2 in human bronchial epithelial cells can contribute to, but is not sufficient for, induction of tumorigenicity in this human model system.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683250

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Cell lines from non-neoplastic liver and hepatocellular carcinoma tissue from a single patient.

Authors:  M Noguchi; S Hirohashi
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-03       Impact factor: 2.416

2.  Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer.

Authors:  Qing Xia; Zhihua Zhu; Jian Wang; Dongrong Situ; Ningning Zhou; Wenqi Jang
Journal:  Tumour Biol       Date:  2012-06-27

Review 3.  Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers.

Authors:  Janakiraman Subramanian; Archana Katta; Ashiq Masood; Dashavantha Reddy Vudem; Rama Krishna Kancha
Journal:  Oncologist       Date:  2019-07-10

4.  Targeted tumor killing via an intracellular antibody against erbB-2.

Authors:  J Deshane; G P Siegal; R D Alvarez; M H Wang; M Feng; G Cabrera; T Liu; M Kay; D T Curiel
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

5.  Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells.

Authors:  K Wiechen; S Karaaslan; A Turzynski; M Dietel
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

6.  Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin.

Authors:  J Y Yoo; X W Wang; A K Rishi; T Lessor; X M Xia; T A Gustafson; A W Hamburger
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

7.  The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells.

Authors:  Donatella Malanga; Carmela De Marco; Ilaria Guerriero; Fabiana Colelli; Nicola Rinaldo; Marianna Scrima; Teresa Mirante; Claudia De Vitis; Pietro Zoppoli; Michele Ceccarelli; Miriam Riccardi; Maria Ravo; Alessandro Weisz; Antonella Federico; Renato Franco; Gaetano Rocco; Rita Mancini; Antonia Rizzuto; Elio Gulletta; Gennaro Ciliberto; Giuseppe Viglietto
Journal:  Oncotarget       Date:  2015-12-15

8.  Mutant AKT1-E17K is oncogenic in lung epithelial cells.

Authors:  Carmela De Marco; Donatella Malanga; Nicola Rinaldo; Fernanda De Vita; Marianna Scrima; Sara Lovisa; Linda Fabris; Maria Vincenza Carriero; Renato Franco; Antonia Rizzuto; Gustavo Baldassarre; Giuseppe Viglietto
Journal:  Oncotarget       Date:  2015-11-24

9.  Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas.

Authors:  W J Rachwal; P F Bongiorno; M B Orringer; R I Whyte; S P Ethier; D G Beer
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.